Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check out whos in charge....
https://libertyhealthsciences.com/
This should not effect a thing?
As they are targeting more than Florida
http://floridapolitics.com/archives/241744-grower-challenge-pot-law
Go APHRIA USA!!!
Welcome aboard ...
New long here. Thought I'd say hello. These guys seem to be one of the only MJ companies that has actually turned a profit lol. long for years here $APHQF
Weeeeeeee cup and handle $8 October 13 2018
Everyone is speculating that when Canada goes legal in 2018 there won't be enough supply to fill demand across the country. Aphria sold 738 kilos in Q4 for $5.7 million. As of next month they will be producing 9000 kilos in the next 12 months. They will have revenues of at least $70 million next year. Hold this stock for years. As they say we have good things growing.
That is just with part 2 expansion.
At the least, they keep chuggin along!
APHRIA about break from out $15 by June 2018 imho
Our 200,000 sq.ft., phase 3 columns are up! This fall we will be ready to harvest 30,000 kgs of Seed-to-Sale Certified #medicalcannabis. Pic on twitter!
Yes sir going long $$$$$$$
Yup , :)
APHRIA going to be king though ...
Lowest cost per gram !!!!
Looking for $15 here :)
Wow 100k shares? Nice! I'm very jelly!!
I got caught waiting for a pullback I know isn't coming :(
Once Heath Canada approves them for the license its game over
That's why I went heavy on mym :) 100 k shares i'm not selling that one the 2019 bro
I got in around October of 2016 @ high 2's then continued buying into 3's.. wish I went heavier in Aphria, my Canopy, Organigram, and Aurora I bought towards end of 2016 haven't performed anywhere nearly as well as Aphria
My average is $5 lol
Remember that one time Aphria dipped to $3.50 for a day? That was fun... good times, good times..
Just looked at chart $5.50 if we break 5.20
If this keeps up EOD .:)
Looks very nice this morning. Could we break $5.25 today?
Sounds like a gameplan! Lol recharge brother ready for that 13.00
I gotta recharge my magic batteries. We need a couple days to consolidate over $5 in a $5.00-5.50 channel then we'll continue our journey to Alpha Centauri 6 hahah
MisterEnzo commanded it lol
Great day guys !!
Also let's not forget 5m contract for plants could be more ?
Exactly prime target for pharma buyout imho , lowest cost producer medical grade !!!!! Talking billions to get bought :)
How great a position is APHQF in where the Canadian government wants to drive out the black market with low pricing and Aphria is the lowest cost producer?
Not really don't forget there huge Florida greenhouse coming soon !
Also who knows what else they announce !!
Aphria gets price target raise to $13.00 at Clarus Securities
July 13, 2017 By Nick Waddell Leave a Comment
Share this:
0
A better than expected quarter has Clarus analyst Noel Atkinson raising his price target on Aphria (TSXV:APH).
On Wednesday, Aphria reported its Q4 and fiscal 2017 results. In the fourth quarter, the company lost $2.6-million on revenue of $5.7-million, a topline that was up 106 per cent over the same period last year.
“”We capped off another exceptional year at Aphria, with increased earnings and lowered all-in production cash costs that provides us with a considerable competitive advantage,” said CEO Vic Neufeld. “We increased our capacity expectations, continued to license the use of the Aphria know-how system to expand our proven operational expertise, made progress on our expansion into the U.S. market — all while maintaining our commitment to delivering clean and safe cannabis. The investments and progress we made in 2017 have positioned Aphria for continued profitable growth, in both the short and long term. As the medical marijuana industry rapidly expands, we believe there is a need to establish a consistent, responsible and transparent definition for licensed producers to calculate their costs to produce dried cannabis per gram. To ensure an accurate peer to peer comparison of this important metric, we are proposing the establishment of an industry-standard definition for costs that includes all costs related to the production of cannabis, including quality control costs.”
Atkinson says the quarter bested his expectations and its performance bodes well for Aphria’s future.
“The Company reported its Q4/FY17 (May) results on July 12, which showed the impressive economies of scale that can be achieved from advanced cultivation techniques in a greenhouse environment during a prime spring growing period,” the analyst says. “Total revenues of $5.7MM beat our $5.3MM estimate, which appears to have been supported by significant new patient growth. Shipments of 738 kg-equivalent of product were well above our 639 kg estimate with minimal (10 kg) wholesale shipments to other LPs and 20% of shipments went to patients onboarded during the quarter. Average price of $7.67/g reflected a modest sequential decline from $7.85/g in Q3, which we believe was driven by product mix and discounts to veterans.”
The analyst says he was particularly impressed with one aspect of the quarterly results.
“What was a real eye-opener for us was the new bar set by Aphria in the industry for production cost. Reported cash production cost per gram (excluding depreciation) of dried cannabis (excluding packaging) dropped to just $1.11/g in Q4, down sharply from a weather-inhibited $1.73/g in Q3 and far better than our $1.63/g estimate. We understand the significant improvement came from a handful of ongoing yield enhancement initiatives, while trim is starting to be utilized in oil extraction and the weather was highly favourable.”
EBITDA increases 181% in the quarter, exceeding $2.8 million
Jul 12, 2017
OTC Disclosure & News Service
-
EBITDA increases 181% in the quarter, exceeding $2.8 million
Cash costs to produce dried cannabis per gram decreases 35% from prior quarter
LEAMINGTON, ONTARIO--(Marketwired - July 12, 2017) - Aphria Inc. ("Aphria" or the "Company") (TSX:APH)(OTCQB:APHQF) today reported its results, for the four quarter and year ended May 31, 2017. All amounts are expressed in Canadian dollars.
Three months ended May 31, Twelve months ended May 31,
2017 2016 2017 2016
$ 5,717,866 $ 2,776,316 Revenue $ 20,438,483 $ 8,433,929
5,826,311 2,106,394 Gross profit 17,297,533 5,977,428
4,902,960 2,069,700 Adjusted gross profit(1) 15,853,608 5,982,074
85.7% 74.5% Adjusted gross margin(1) 77.6% 70.9%
(2,592,742) 1,302,164 Net income (loss) 4,198,455 397,961
2,826,667 520,685 EBITDA(1) 6,082,546 572,888
Q4-2017 Q3-2017
738.3 Kilograms (or kilogram equivalents) sold 652.7
$ 5,717,866 Revenue $ 5,118,516
$ 2,826,667 EBITDA(1) $ 1,005,073
$ 0.79 Cash cost to produce dried cannabis / gram - using competitors' definition(1) $ 1.42
$ 1.11 Cash cost to produce dried cannabis / gram - using Aphria's definition(1) $ 1.73
$ 1.67 "All-in" cost of goods sold / gram(1) $ 2.23
$ 84,351,132 Cash and cash equivalents & marketable securities $ 122,029,195
$ 123,144,983 Working capital $ 123,144,983
$ 23,419,877 Investment in capital and intangible assets $ 23,419,877
Operating highlights
•Seventh consecutive quarter of positive EBITDA. $2.8 million in EBITDA in the quarter, a 181% increase from the prior quarter, and $6.1 million for the year, a 962% increase year-over-year.
•Increased our annual production capacity expectations for Part II (to 9,000 kgs), Part III (to 30,000 kgs) & to Part IV (100,000 kgs) expansion projects.
•Received Health Canada approval for our Part II expansion. First harvest in the new expansion will occur in the middle of July. First sale, from the plants grown in the expansion, is expected in mid-August 2017 (late in Q1).
•Improved "all-in" costs to produce dried cannabis per gram from $2.23 to $1.67 in the quarter, a decrease of 25%.
•Improved cash costs to produce dried cannabis per gram from $1.73 to $1.11 in the quarter, a decrease of 36%, based on Aphria's definition. Some of our competitors are using a definition different from Aphria's for cash costs to produce. Applying their definition to our results, Aphria's cash cost to produce per gram decreased from $1.42 to $0.79, a decrease of 44%.
•Exercised our conversion rights on the unsecured convertible debentures of SecureCom Mobile Inc. ("SecureCom") in exchange for 4,000,000 shares and exercised our warrant, purchasing an additional 4,000,000 shares @ $0.08 per share bringing our total investment in SecureCom to 8,000,000 shares at a cost of $520,000. As at May 31, 2017, the fair value of the SecureCom shares was $1,664,000.
•Licensed the use of the Aphria Know-How System, as further detailed in the MD&A being filed concurrently with this release, to DFMMJ Investments, Ltd. ("DFMMJ"), in exchange for 192,400,000 shares in DFMMJ.
•Invested approximately $25 million in DFMMJ, which DFMMJ used, along with other monies raised via a private placement, to acquire all or substantially all of the assets of Chestnut Hill Tree Farm LLC, in exchange for in excess of 120,000,000 shares of DFMMJ, in addition to our existing DFMMJ shares.
•Received final approval to list on the Toronto Stock Exchange ("TSX"). Shares commenced trading on the TSX and were delisted from the TSX-Venture Exchange on March 22, 2017.
•Closed May bought deal and debt financing raising over $105 million in additional proceeds to fully fund our Part IV expansion project, fully fund our working capital needs after completion of the expansion project and raised funds for additional strategic investments.
"We capped off another exceptional year at Aphria, with increased earnings and lowered all-in production cash costs that provides us with a considerable competitive advantage," said Vic Neufeld, Chief Executive Officer, Aphria. "We increased our capacity expectations, continued to license the use of the Aphria Know-How System to expand our proven operational expertise, made progress on our expansion into the US market - all while maintaining our commitment to delivering clean and safe cannabis. The investments and progress we made in 2017 have positioned Aphria for continued profitable growth, in both the short and long term."
"As the medical marijuana industry rapidly expands, we believe there is a need to establish a consistent, responsible and transparent definition for licensed producers to calculate their costs to produce dried cannabis per gram. To ensure an accurate peer to peer comparison of this important metric, we are proposing the establishment of an industry standard definition for costs that includes all costs related to the production of cannabis, including quality control costs."
Financial highlights
For the seventh consecutive quarter, the Company reported positive EBITDA. In the quarter, the Company reported $2.8 million in EBITDA, a 181% increase over the prior quarter and for the year ended May 31, 2017, reported $6.1 million in EBITDA, a 961% increase over the prior year. The Company remains committed to the responsible use of our shareholders' investment in Aphria. The Company continues to invest in its recreational brand, continues to proceed diligently on its capital investment plans and continues to explore other opportunities to increase shareholder value, while ensuring appropriate liquidity risk mitigation strategies are in place.
Revenue for the three months ended May 31, 2017 was $5,717,866, representing a 11.7% increase over the prior quarter's revenue of $5,188,516, in a quarter in which the Company was capacity constrained. The Company's exceptional March and May harvests, along with its inventory levels, allowed the Company to sell more than its expected quarterly production of 650 kgs. Cannabis oil sales, as a percentage of all revenue, continued to grow in the quarter, increasing to 32% of revenue.
For the year ended May 31, 2017, revenue was $20,438,483 versus $8,433,929 in the year ended May 31, 2016, an increase of 142%.
Adjusted gross profit for the fourth quarter was $4,902,960 with an adjusted gross margin of 85.7%, generated from both retail and wholesale shipments of medical cannabis. The increase in the adjusted gross margin from the prior quarter is consistent with the increase in revenues combined with improved cost structures.
Adjusted gross profit for the year was $15,853,608, with an adjusted gross margin of 77.6%.
During the quarter, our "all-in" costs of dried cannabis per gram decreased from $2.23 to $1.67. The decrease largely related to improved growing techniques and better cooperation from Mother Nature. Similarly, our cash costs of dried cannabis per gram decreased from $1.73 to $1.11, using Aphria's standard definition.
While the Company believes strongly in its definition of cash costs to produce dried cannabis per gram, certain of its publicly traded competitors are disclosing a similarly titled metric but for which they are using a different definition of cash costs. The primary differences between Aphria's definition and certain competitors' definition is that Aphria's definition includes the costs related to indirect labour expenses and quality control costs. Aphria believes that both of these expenses should be included in any cash cost calculation. However, for the sole purpose of presenting a figure which is comparable to this other definition, we re-calculated our cash costs to produce dried cannabis per gram by deducting so-called post production costs from our cash cost to produce dried cannabis and divided that sum by gram equivalents sold in the quarter. Using this definition of cash costs to produce dried cannabis, Aphria's fourth quarter figure is $0.79 per gram.
Net loss for the three months ended May 31, 2017 was $2,592,742 or $0.02 per share as opposed to a net income of $1,302,164 or $0.02 per share in the same quarter in the previous year and an income before tax of $4,950,250 or $0.04 per share in the previous quarter. The decrease in net income for Aphria in the quarter is directly related to the more than $5.5 million net loss on the Company's strategic investments in the quarter.
Net income for the year ended May 31, 2017 was $4,198,455 or $0.04 per share versus net income of $397,961 in the prior year. Included in the net income for the 2017 year was a gain on the Company's investment portfolio of almost $3.6 million and a write-off of the Company's intangible asset, related to its CannWay brand, of $3.5 million.
EBITDA for the fourth quarter was $2,826,667, compared to an EBITDA of $520,685 in the same period of the prior year and EBITDA of $1,005,516 in the previous quarter.
EBITDA for the year ended May 31, 2017 was $6,082,546 compared to EBITDA of $572,888 in the prior year.
We have A Good Thing Growing.
(1) In this press release, reference is made to "all-in" costs to produce dried cannabis per gram, cash costs to produce dried cannabis, cash costs to produce dried cannabis per gram, adjusted gross profit, adjusted gross margin and EBITDA, which are not measures of financial performance under International Financial Reporting Standards. Definitions for all terms above can be found in the Company's May 31, 2017 Management's Discussion and Analysis, filed on SEDAR.
About Aphria
Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.
For more information, visit www.Aphria.com.
Yup, they'll overtake Tweeds market cap eventually.
Once Aphria claims #1 spot, so much money will flow I bet it hits $20 by Q4 2018. That is ridiculously bullish but it's very possible
Phrase about to take its place as king ....
Tweed 300 m in debt !! Rofl
Could Aphria Inc. Be the Turnaround Play of the Year?
After dropping nearly 30% from its all-time high three months ago, shares of Canadian cannabis producer Aphria Inc. (TSX:APH) appear to once again be on the rise. The company recently reported very strong earnings, announcing production efficiencies which have resulted in Aphria boasting the lowest production costs in the industry for the commodity.
Aphria’s trailing twelve month earnings are also positive, something which other large marijuana producers such as Canopy Growth Corp. (TSX:WEED) and Aurora Cannabis Inc. (TSXV:ACB) cannot say at the moment.
\Investors looking to place their bets on the company that should come out ahead in the Canadian "green rush" have largely taken their money off the table of late, given a relatively poor showing by the industry following outsized growth expectations that have not panned out in the short-term.
Aphria’s recent earnings results, however, have sparked renewed interest in the industry from a long-term profitability standpoint, something which has resulted in an industry-wide boost in market capitalizations for the majority of publicly traded Canadian marijuana firms this past week.
While I have remained bearish on the rollout of the marijuana industry in Canada (I just don’t have much faith in the Canadian government to roll out the legalization process well), as well as the long-term effects of supply and demand which appear to be out of whack, given Aphria’s current position as a cost leader in this space, I would argue that this is one company which is worth a second look by investors interested in this sector.
Lol back at ya, lets go
Yaaas!! Now let's head toward $6.30 haha
Let's gooo
Lol missed it by that much! Tomorrow we crush it!
I command you to break $5!!!
Followers
|
330
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
16650
|
Created
|
10/02/16
|
Type
|
Free
|
Moderators |
https://aphria.ca/
PO Box 20009 269 Erie St South
Leamington, ON N8H 3C4
214 King Street West, Suite 412 Toronto,
ON M5H 3S6
Aphria is a Health Canada Licensed Producer of medical cannabis products. Our quality medical cannabis is 100% greenhouse grown.
100% Greenhouse Grown- Our plants thrive from the many benefits of natural sunlight in our state-of-the-art greenhouse.
Safe and Consistent Products- Aphria goes beyond industry standards to ensure patients receive clean, safe, and pure medical cannabis products.
Superior Patient Care- Our compassionate and knowledgeable Patient Care Team is here to assist you every step of the way.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |